GOALS  Autoimmune disease develops when the immune system “goes rogue” and destroys normal healthy cells in the body. Immune Thrombocytopenia (ITP) is a serious bleeding disorder caused by immune destruction of platelets, small blood cells that heal injured blood vessels. The treatment of ITP involves long courses of powerful immunosuppressive drugs that require frequent rechecks for monitoring. Common side effects of these drugs include urinary incontinence, hair loss, intestinal ulcers, and can be as severe as bone marrow failure or sepsis. Our study aims to understand the cause of immune-targeted platelet destruction. The results will help veterinarians optimize treatment for each canine patient in order to minimize treatment side effects.

ELIGIBILITY  Dogs seen by Cornell University Hospital for Animals (or a number of participating hospitals) with severe thrombocytopenia (<50,000/uL) and evidence of immune mediated platelet destruction.

COMPENSATION  The study will cover the costs of coagulation testing at the time of diagnosis.

OWNER RESPONSIBILITIES  If you agree to let your dog participate in this study, you are consenting to collection of a one-time blood sample from your dog at the time of diagnosis of ITP.

PARTICIPATING INSTITUTIONS  Cornell University Veterinary Specialists (Stamford, CT), Iowa State University College of Veterinary Medicine (Ames, IA), Veterinary Specialists & Emergency Services (Rochester, NY), Oradell Animal Hospital (Paramus, NJ)

Principal Investigator
Marjory Brooks, DVM, DACVIM

Contact Information
(607) 253-3060
vet-research@cornell.edu